Skip to main content

Neuropharmacology

  • ISSN: 0028-3908

Editor-In-Chief: Frenguelli

Next planned ship date: April 8, 2024

  • 5 Year impact factor: 4.8
  • Impact factor: 4.7

Neuropharmacology publishes high quality, original research within the discipline of neuroscience. The emphasis of Neuropharmacology is on the study and understanding of the actio… Read more

Subscription options

Next planned ship date:
April 8, 2024

Institutional subscription on ScienceDirect

Request a sales quote


Neuropharmacology publishes high quality, original research within the discipline of neuroscience. The emphasis of Neuropharmacology is on the study and understanding of the actions of known exogenous and endogenous chemical agents on neurobiological processes in the mammalian nervous system. Work with non-mammalian and invertebrate species may be considered in exceptional circumstances. The journal does not usually accept clinical research, although neuropharmacological studies in humans may be considered on the condition that they provide novel insight into either the actions of drugs and/or neurobiological mechanisms. The journal only considers submissions in which the chemical structures and compositions of experimental agents are readily available in the literature or disclosed by the authors in the submitted manuscript. Similarly, manuscripts describing the use of natural products will only be considered if the active ingredient is known and disclosed.


The journal publishes Special Issues in which leading experts are invited to serve as Guest Editors to compile a collection of reviews, and occasionally original articles, around a particular topical theme in neuroscience research. The list of recent Special Issues can be found here. Suggestions for Special Issues can be made directly to the Editor-in-Chief.

Neuropharmacology also publishes topical narrative reviews on subjects within its remit. These reviews are commissioned by the Editorial Team or arise after correspondence with potential authors. Unsolicited reviews will be considered, but authors are encouraged to contact the Editor-in-Chief of their intention to submit a review. Potential review authors should clearly indicate their expertise in the area, and how the review differs from, and adds to, recent published reviews on related topics. On the basis of the case made by authors, potential overlap with planned Neuropharmacology content, and discussions with the Editorial Team, the Editor-in-Chief will provide authors with a prompt decision regarding the proposed review. Systematic reviews, meta- or bibliographic analyses will not be considered unless they are a necessary part of a Special Issue and conducted by experts in the field, and even then only under exceptional circumstances and at the discretion of the Editor-in-Chief.